We have not reviewed the charts of United Therapeutics Corporation (UTHR) since Dec. 8, 2017 and then we had a long-term Point and Figure target of $175. Prices finally reached that long-term price target this year.




We have not reviewed the charts of United Therapeutics Corporation (UTHR) since Dec. 8, 2017 and then we had a long-term Point and Figure target of $175. Prices finally reached that long-term price target this year.
Look for more positioning on Tuesday ahead of two important economic reports.
The stock has surged amid an analyst upgrade.
The stock just tested the underside of the declining 50-day moving average.
Here's what the longer-term picture looks like.
Sentiment is starting to turn bullish, but painted with a skeptical eye as the wall of worry is up high.
We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.
Email Real Money's Wall Street Pros for further analysis and insight
Already a Subscriber? Login
Follow Real Money's Wall Street Pros to receive real-time investing alerts
Already a Subscriber? Login